Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product ...

The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their ...

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of ...

Not long after the first flu shot was introduced in 1945 by University of Michigan virologist Thomas Francis and his ...

Oruka Therapeutics (ORKA) announced new preclinical data on ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F, from ...

New research highlights a critical link between antibodies produced against Epstein-Barr virus (EBV) and the development of ...

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimeki ...